| abstract |
According to the present disclosure, macrocyclic compounds capable of binding to PD-L1 and inhibiting the interaction of PD-L1 with PD-1 and CD80 were discovered. These macrocyclic compounds have shown immunomodulatory efficacy in vitro, making them therapeutic candidates for the treatment of various diseases, including cancer and infectious diseases. |